Literature DB >> 24954733

Poly (γ-glutamic acid) based combination of water-insoluble paclitaxel and TLR7 agonist for chemo-immunotherapy.

Anushree Seth1, Min Beom Heo1, Yong Taik Lim2.   

Abstract

Advanced anti-cancer regimens are being introduced for more effective cancer treatment with improved life expectancy. In this research, immuno-stimulating agent toll-like receptor-7 (TLR-7) agonist-imiquimod and low dose chemotherapeutic agent-paclitaxel were synergized to demonstrate tumor therapy along with anti-tumor memory effect. Both therapeutic agents being water insoluble were dispersed in water with the help of water soluble polymer: poly (γ-glutamic acid) (γ-PGA) using a co-solvent systems leading to formation of micro-dispersions of drugs. Paclitaxel and imiquimod formed crystalline microstructures in the size range of 2-3 μm and were stably dispersed in γ-PGA matrix for more than 6 months. Paclitaxel and combination of paclitaxel and imiquimod had significant tumor killing effect in-vitro on various tumor cell lines, while antigen presenting cells (dendritic cells-DCs) treated with the same concentration of imiquimod along with the combination led to enhanced proliferation (250%). In DCs, enhanced secretion of pro-inflammatory and Th1 cytokines was observed in cells co-treated with paclitaxel and imiquimod dispersed in γ-PGA. When administered by intra-tumoral injection in mouse melanoma tumor model, the treatment with combination exemplified drastic inhibition of tumor growth leading to 70% survival as compared to individual components with 0% survival at day 41. The anti-tumor response generated was also found to have systemic memory response since the vaccinated mice significantly deferred secondary tumor development at distant site 6 weeks after treatment. The relative number and activation status of DCs in-vivo was found to be dramatically increased in case of mice treated with combination. The dramatic inhibition of tumor treated with combination is expected to be mediated by both chemotherapeutic killing of tumor cells followed by uptake of released antigen by the DCs and due to enhanced proliferation and activation of the DCs.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Combination therapy; Drug delivery; Immuno-stimulation; Poly(γ-glutamic acid)

Mesh:

Substances:

Year:  2014        PMID: 24954733     DOI: 10.1016/j.biomaterials.2014.05.076

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  15 in total

Review 1.  Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.

Authors:  Nazila Kamaly; Basit Yameen; Jun Wu; Omid C Farokhzad
Journal:  Chem Rev       Date:  2016-02-08       Impact factor: 60.622

2.  Fatty Acid-Mimetic Micelles for Dual Delivery of Antigens and Imidazoquinoline Adjuvants.

Authors:  Sema Sevimli; Frances C Knight; Pavlo Gilchuk; Sebastian Joyce; John T Wilson
Journal:  ACS Biomater Sci Eng       Date:  2016-11-09

3.  Vitamin E-rich Nanoemulsion Enhances the Antitumor Efficacy of Low-Dose Paclitaxel by Driving Th1 Immune Response.

Authors:  Jun Ye; Wujun Dong; Yanfang Yang; Huazhen Hao; Hengfeng Liao; Bangyuan Wang; Xue Han; Yiqun Jin; Xuejun Xia; Yuling Liu
Journal:  Pharm Res       Date:  2017-03-21       Impact factor: 4.200

Review 4.  Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment.

Authors:  Kasturee Chakraborty; Archana Tripathi; Sukumar Mishra; Argha Mario Mallick; Rituparna Sinha Roy
Journal:  Biosci Rep       Date:  2022-07-29       Impact factor: 3.976

5.  Shape-Dependent Biodistribution of Biocompatible Silk Microcapsules.

Authors:  Sisi Cao; Rui Tang; Gail Sudlow; Zheyu Wang; Keng-Ku Liu; Jingyi Luan; Sirimuvva Tadepalli; Anushree Seth; Samuel Achilefu; Srikanth Singamaneni
Journal:  ACS Appl Mater Interfaces       Date:  2019-01-28       Impact factor: 9.229

Review 6.  Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy.

Authors:  Xiaopin Duan; Christina Chan; Wenbin Lin
Journal:  Angew Chem Int Ed Engl       Date:  2018-11-15       Impact factor: 15.336

Review 7.  Nanotechnology synergized immunoengineering for cancer.

Authors:  Deepak S Chauhan; Anupam Dhasmana; Partha Laskar; Rajendra Prasad; Nishant K Jain; Rohit Srivastava; Meena Jaggi; Subhash C Chauhan; Murali M Yallapu
Journal:  Eur J Pharm Biopharm       Date:  2021-03-24       Impact factor: 5.589

8.  Nanoparticles for Effective Combination Therapy of Cancer.

Authors:  Rahul Jadia; Cody Scandore; Prakash Rai
Journal:  Int J Nanotechnol Nanomed       Date:  2016-10-30

9.  Combining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.

Authors:  Anushree Seth; Hyunseung Lee; Mi Young Cho; Cheongsoo Park; Sovannarith Korm; Joo-Yong Lee; Inpyo Choi; Yong Taik Lim; Kwan Soo Hong
Journal:  Oncotarget       Date:  2017-01-17

10.  Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy.

Authors:  Min Beom Heo; Sun-Young Kim; Wan Soo Yun; Yong Taik Lim
Journal:  Int J Nanomedicine       Date:  2015-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.